Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
Abstract Background Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lung cancer. Our aim was to analyze the association between serum biomarke...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-017-3285-6 |
| _version_ | 1798045411789766656 |
|---|---|
| author | Kota Nakamura Motoyasu Kato Takehito Shukuya Keita Mori Yasuhito Sekimoto Hiroaki Ihara Ryota Kanemaru Ryo Ko Rina Shibayama Ken Tajima Ryo Koyama Naoko Shimada Osamu Nagashima Fumiyuki Takahashi Shinichi Sasaki Kazuhisa Takahashi |
| author_facet | Kota Nakamura Motoyasu Kato Takehito Shukuya Keita Mori Yasuhito Sekimoto Hiroaki Ihara Ryota Kanemaru Ryo Ko Rina Shibayama Ken Tajima Ryo Koyama Naoko Shimada Osamu Nagashima Fumiyuki Takahashi Shinichi Sasaki Kazuhisa Takahashi |
| author_sort | Kota Nakamura |
| collection | DOAJ |
| description | Abstract Background Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lung cancer. Our aim was to analyze the association between serum biomarkers sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), and clinical characteristics in patients diagnosed with ILD-AA. Methods Between April 2011 and March 2016, 1224 advanced lung cancer patients received cytotoxic agents and epidermal growth factor receptor tyrosine kinase inhibitors at Juntendo University Hospital and Juntendo University Urayasu Hospital. Of these patients, those diagnosed with ILD-AA were enrolled in this case control study. ΔKL-6 and ΔSP-D were defined as the difference between the levels at the onset of ILD-AA and their respective levels prior to development of ILD-AA. We evaluated KL-6 and SP-D at the onset of ILD-AA, ΔKL-6 and ΔSP-D, the risk factors for death related to ILD-AA, the chest high resolution computed tomography (HRCT) findings, and survival time in patients diagnosed with ILD-AA. Results Thirty-six patients diagnosed with ILD-AA were enrolled in this study. Among them, 14 patients died of ILD-AA. ΔSP-D in the patients who died was significantly higher than that in the patients who survived. However, ΔKL-6 did not differ significantly between the two groups. Moreover, ΔSP-D in patients who exhibited diffuse alveolar damage was significantly higher than that in the other patterns on HRCT. Receiver operating characteristic curve analysis was used to set the optimal cut off value for ΔSP-D at 398 ng/mL. Survival time for patients with high ΔSP-D (≥ 398 ng/mL) was significantly shorter than that for patients with low ΔSP-D. Multivariate analysis revealed that ΔSP-D was a significant prognostic factor of ILD-AA. Conclusions This is the first research to evaluate high ΔSP-D (≥ 398 ng/mL) in patients with ILD-AA and to determine the risk factors for ILD-AA in advanced lung cancer patients. ΔSP-D might be a serum prognostic biomarker of ILD-AA. Clinicians should evaluate serum SP-D during chemotherapy and should carefully monitor the clinical course in patients with high ΔSP-D. |
| first_indexed | 2024-04-11T23:20:27Z |
| format | Article |
| id | doaj.art-de4861a09d9b4a83aa05f98ca63d3cd5 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-11T23:20:27Z |
| publishDate | 2017-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-de4861a09d9b4a83aa05f98ca63d3cd52022-12-22T03:57:28ZengBMCBMC Cancer1471-24072017-05-0117111010.1186/s12885-017-3285-6Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control studyKota Nakamura0Motoyasu Kato1Takehito Shukuya2Keita Mori3Yasuhito Sekimoto4Hiroaki Ihara5Ryota Kanemaru6Ryo Ko7Rina Shibayama8Ken Tajima9Ryo Koyama10Naoko Shimada11Osamu Nagashima12Fumiyuki Takahashi13Shinichi Sasaki14Kazuhisa Takahashi15Department of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineClinical Trial Coordination Office, Shizuoka Cancer CenterDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineDepartment of Respiratory Medicine, Juntendo University Graduate School of MedicineAbstract Background Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lung cancer. Our aim was to analyze the association between serum biomarkers sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), and clinical characteristics in patients diagnosed with ILD-AA. Methods Between April 2011 and March 2016, 1224 advanced lung cancer patients received cytotoxic agents and epidermal growth factor receptor tyrosine kinase inhibitors at Juntendo University Hospital and Juntendo University Urayasu Hospital. Of these patients, those diagnosed with ILD-AA were enrolled in this case control study. ΔKL-6 and ΔSP-D were defined as the difference between the levels at the onset of ILD-AA and their respective levels prior to development of ILD-AA. We evaluated KL-6 and SP-D at the onset of ILD-AA, ΔKL-6 and ΔSP-D, the risk factors for death related to ILD-AA, the chest high resolution computed tomography (HRCT) findings, and survival time in patients diagnosed with ILD-AA. Results Thirty-six patients diagnosed with ILD-AA were enrolled in this study. Among them, 14 patients died of ILD-AA. ΔSP-D in the patients who died was significantly higher than that in the patients who survived. However, ΔKL-6 did not differ significantly between the two groups. Moreover, ΔSP-D in patients who exhibited diffuse alveolar damage was significantly higher than that in the other patterns on HRCT. Receiver operating characteristic curve analysis was used to set the optimal cut off value for ΔSP-D at 398 ng/mL. Survival time for patients with high ΔSP-D (≥ 398 ng/mL) was significantly shorter than that for patients with low ΔSP-D. Multivariate analysis revealed that ΔSP-D was a significant prognostic factor of ILD-AA. Conclusions This is the first research to evaluate high ΔSP-D (≥ 398 ng/mL) in patients with ILD-AA and to determine the risk factors for ILD-AA in advanced lung cancer patients. ΔSP-D might be a serum prognostic biomarker of ILD-AA. Clinicians should evaluate serum SP-D during chemotherapy and should carefully monitor the clinical course in patients with high ΔSP-D.http://link.springer.com/article/10.1186/s12885-017-3285-6Interstitial lung diseaseDrug-induced interstitial lung diseaseLung cancer |
| spellingShingle | Kota Nakamura Motoyasu Kato Takehito Shukuya Keita Mori Yasuhito Sekimoto Hiroaki Ihara Ryota Kanemaru Ryo Ko Rina Shibayama Ken Tajima Ryo Koyama Naoko Shimada Osamu Nagashima Fumiyuki Takahashi Shinichi Sasaki Kazuhisa Takahashi Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study BMC Cancer Interstitial lung disease Drug-induced interstitial lung disease Lung cancer |
| title | Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study |
| title_full | Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study |
| title_fullStr | Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study |
| title_full_unstemmed | Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study |
| title_short | Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study |
| title_sort | surfactant protein d predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer a case control study |
| topic | Interstitial lung disease Drug-induced interstitial lung disease Lung cancer |
| url | http://link.springer.com/article/10.1186/s12885-017-3285-6 |
| work_keys_str_mv | AT kotanakamura surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT motoyasukato surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT takehitoshukuya surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT keitamori surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT yasuhitosekimoto surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT hiroakiihara surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT ryotakanemaru surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT ryoko surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT rinashibayama surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT kentajima surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT ryokoyama surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT naokoshimada surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT osamunagashima surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT fumiyukitakahashi surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT shinichisasaki surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy AT kazuhisatakahashi surfactantproteindpredictsprognosisofinterstitiallungdiseaseinducedbyanticanceragentsinadvancedlungcanceracasecontrolstudy |